Literature DB >> 27881848

Expression and methylation of circulating microRNA-510 in essential hypertension.

Ramalingam Krishnan1, Panagal Mani2, Pethanen Sivakumar3, Vincent Gopinath3, Durairaj Sekar1.   

Abstract

Hypertension (HTN) is one of the most common emerging disease in developing countries. It alters endothelial cell structure and function, resulting in several diseases, such as cardiovascular disease, peripheral vasculopathy, cerebrovascular disease and nephropathy. Although much progress has been made in researching HTN in recent years, early diagnosis and treatment of HTN are not yet satisfactory, and progression control/treatment is still poor. MicroRNAs are well-known regulators of the physiological and developmental processes of HTN. Our results revealed that miR-510 was upregulated in blood samples from HTN patients, whereas no significant differences were observed in the control samples. Methylation analyses corroborated the miR-510 upregulation in patient samples. These results suggested that miR-510 can be used as a novel biomarker for diagnosis and as a new therapeutic target for HTN.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27881848     DOI: 10.1038/hr.2016.147

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  22 in total

1.  DNA methylation silences miR-132 in prostate cancer.

Authors:  A Formosa; A M Lena; E K Markert; S Cortelli; R Miano; A Mauriello; N Croce; J Vandesompele; P Mestdagh; E Finazzi-Agrò; A J Levine; G Melino; S Bernardini; E Candi
Journal:  Oncogene       Date:  2012-02-06       Impact factor: 9.867

2.  Aberrant methylation of DNA mismatch repair genes in elderly patients with sporadic gastric carcinoma: A comparison with younger patients.

Authors:  Ho Gun Kim; Soon Lee; Dong Yi Kim; Seong Yeob Ryu; Jae Kyun Joo; Jung Chul Kim; Kyung Hwa Lee; Jae Hyuk Lee
Journal:  J Surg Oncol       Date:  2010-01-01       Impact factor: 3.454

3.  Responding to the threat of chronic diseases in India.

Authors:  K Srinath Reddy; Bela Shah; Cherian Varghese; Anbumani Ramadoss
Journal:  Lancet       Date:  2005-11-12       Impact factor: 79.321

Review 4.  Role of microRNA 21 in mesenchymal stem cell (MSC) differentiation: a powerful biomarker in MSCs derived cells.

Authors:  Durairaj Sekar; Subramanian Saravanan; Kulandaivelu Karikalan; Krishnaraj Thirugnanasambantham; Perumal Lalitha; Villianur I H Islam
Journal:  Curr Pharm Biotechnol       Date:  2015       Impact factor: 2.837

5.  Correlation between hypertension and hyperglycemia among young adults in India.

Authors:  Tanu Midha; Vinay Krishna; Rishi Shukla; Praveen Katiyar; Samarjeet Kaur; Dinesh Singh Martolia; Umeshwar Pandey; Yashwant Kumar Rao
Journal:  World J Clin Cases       Date:  2015-02-16       Impact factor: 1.337

Review 6.  How epigenetics can explain human metastasis: a new role for microRNAs.

Authors:  Amaia Lujambio; Manel Esteller
Journal:  Cell Cycle       Date:  2009-02-01       Impact factor: 4.534

Review 7.  Relevance of miR-21 in HIV and non-HIV-related lymphomas.

Authors:  Durairaj Sekar; Villianur Ibrahim Hairul Islam; Krishnaraj Thirugnanasambantham; Subramanian Saravanan
Journal:  Tumour Biol       Date:  2014-06-25

Review 8.  Trends in hypertension epidemiology in India.

Authors:  R Gupta
Journal:  J Hum Hypertens       Date:  2004-02       Impact factor: 3.012

9.  Reprint of: miRNA-1 regulates endothelin-1 in diabetes.

Authors:  Biao Feng; Yanan Cao; Shali Chen; Michael Ruiz; Subrata Chakrabarti
Journal:  Life Sci       Date:  2014-10-13       Impact factor: 5.037

10.  Specific and sensitive quantitative RT-PCR of miRNAs with DNA primers.

Authors:  Ingrid Balcells; Susanna Cirera; Peter K Busk
Journal:  BMC Biotechnol       Date:  2011-06-25       Impact factor: 2.563

View more
  11 in total

Review 1.  Noncoding RNAs in the Regulatory Network of Hypertension.

Authors:  Gengze Wu; Pedro A Jose; Chunyu Zeng
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

2.  Comment on the potential role of microRNAs in hypertension.

Authors:  Durairaj Sekar
Journal:  J Hum Hypertens       Date:  2018-09-19       Impact factor: 3.012

Review 3.  Relevance of microRNA 21 in Different Types of Hypertension.

Authors:  Durairaj Sekar; B R Shilpa; Anupam J Das
Journal:  Curr Hypertens Rep       Date:  2017-07       Impact factor: 5.369

Review 4.  Epigenetic modification: a regulatory mechanism in essential hypertension.

Authors:  Mohammed Arif; Sakthivel Sadayappan; Richard C Becker; Lisa J Martin; Elaine M Urbina
Journal:  Hypertens Res       Date:  2019-03-13       Impact factor: 3.872

Review 5.  Impact of Nutritional Epigenetics in Essential Hypertension: Targeting microRNAs in the Gut-Liver Axis.

Authors:  Johnathan Kawika Cooper; Rochell Issa; Pratyush Pavan Devarasetty; Rachel M Golonka; Veda Gokula; Joshua Busken; Jasenka Zubcevic; Jennifer Hill; Matam Vijay-Kumar; Bindu Menon; Bina Joe
Journal:  Curr Hypertens Rep       Date:  2021-05-07       Impact factor: 5.369

Review 6.  Non-Coding RNA in the Pathogenesis, Progression and Treatment of Hypertension.

Authors:  Christiana Leimena; Hongyu Qiu
Journal:  Int J Mol Sci       Date:  2018-03-21       Impact factor: 5.923

Review 7.  The regulatory role of microRNAs in angiogenesis-related diseases.

Authors:  Li-Li Sun; Wen-Dong Li; Feng-Rui Lei; Xiao-Qiang Li
Journal:  J Cell Mol Med       Date:  2018-06-29       Impact factor: 5.310

Review 8.  Noncoding RNAs in Hypertension.

Authors:  Amela Jusic; Yvan Devaux
Journal:  Hypertension       Date:  2019-07-29       Impact factor: 10.190

Review 9.  Epigenetic Biomarkers in Cardiovascular Diseases.

Authors:  Carolina Soler-Botija; Carolina Gálvez-Montón; Antoni Bayés-Genís
Journal:  Front Genet       Date:  2019-10-09       Impact factor: 4.599

10.  Exosomal MicroRNAs Contribute to Cognitive Impairment in Hypertensive Patients by Decreasing Frontal Cerebrovascular Reactivity.

Authors:  Junyi Ma; Xiang Cao; Fangyu Chen; Qing Ye; Ruomeng Qin; Yue Cheng; Xiaolei Zhu; Yun Xu
Journal:  Front Neurosci       Date:  2021-03-01       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.